Small-cap equities frequently trade at discounts to intrinsic value due to limited sell-side coverage and lower institutional ownership, but that dynamic can reverse sharply when a defined catalyst arrives.
The eight companies below, drawn from TipRanks analyst consensus data, span biotechnology, defense systems, aerospace, and critical minerals, sectors where clinical readouts, contract awards, and permitting milestones can reprice a stock within a compressed timeframe.
Lantern Pharma Inc. (NASDAQ: LTRN)
Source: Lantern Pharma Inc.
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage oncology company whose proprietary RADR artificial intelligence platform analyzes genomic data to identify patient subpopulations most likely to respond to targeted cancer therapies. Its lead asset, LP-184, completed Phase 1a with a reported 54% disease control rate in 63 heavily pre-treated patients. LP-284 received its sixth FDA Orphan Drug Designation in January 2026. The company reports Q4 and full-year 2025 results on March 30, 2026 -- an immediate near-term catalyst. Lake Street carries a Strong Buy rating with a $25.00 price target.
Learn more about Lantern Pharma Inc.
BioVie Inc. (NASDAQ: BIVI)
Source: BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is advancing bezisterim (NE3107), an oral anti-inflammatory compound, in Parkinson's and Alzheimer's disease. The company recently completed enrollment in its SUNRISE-PD Phase 2 Parkinson's trial, positioning the stock ahead of a data readout that represents the primary value catalyst. Brookline Capital Markets carries a Buy rating with an average price target of $12.00, the sole analyst on TipRanks, implying approximately 751% upside. Single-analyst coverage carries higher uncertainty and should be weighted accordingly.
Connect Biopharma Holdings Limited (NASDAQ: CNTB)
Source: Connect Biopharma Holdings Ltd.
Connect Biopharma Holdings Limited (NASDAQ: CNTB) is developing rademikibart, a monoclonal antibody targeting the IL-4 receptor alpha subunit, in asthma and inflammatory respiratory conditions -- the same validated pathway as dupilumab (Dupixent), which generated approximately €13 billion in global net sales in 2024 per Sanofi's full-year financial results. Four analysts on TipRanks carry a Strong Buy consensus with an average price target of $8.67, ranging from a low of $7.00 to a high of $10.00, implying approximately 214% upside at the average. Clinical data readouts represent the primary near-term catalyst.
Learn more about Connect Biopharma Holdings Ltd.
XTI Aerospace, Inc. (NASDAQ: XTIA)
Source: XTI Aerospace, Inc.
XTI Aerospace, Inc. (NASDAQ: XTIA) operates through two platforms: the TriFan 600 vertical takeoff and landing aircraft in development, and Drone Nerds, an enterprise drone distributor acquired in late 2025. Management stated at a February 2026 shareholder update that Drone Nerds generated more than $110 million in 2024 revenue and that the company expects 2026 revenue to exceed $160 million. XTI also secured a $20 million revolving credit facility with JPMorgan Chase in February 2026. TipRanks currently shows a single analyst with an average price target of $3.00, roughly in line with the current price, reflecting limited sell-side coverage. Pending submissions to three U.S. defense programs -- DIU RIMES, DIU CADDS, and the DARPA Lift Challenge -- represent the primary near-term catalysts.
Learn more about XTI Aerospace Inc.
Red Cat Holdings, Inc. (NASDAQ: RCAT)
Source: Red Cat Holdings, Inc.
Red Cat Holdings, Inc. (NASDAQ: RCAT) manufactures tactical drone platforms, including the Black Widow reconnaissance system, for U.S. defense and intelligence customers. The company reported record Q4 2025 revenue following the expansion of its U.S. Army LRIP contract for Black Widow systems to $35.1 million, though widening net losses accompanied the revenue growth. Three analysts on TipRanks carry a Strong Buy consensus with an average price target of $17.67, ranging from a low of $15.00 to a high of $22.00, implying approximately 19% upside at the average. Management has indicated comfort with the top half of Wall Street's $100 million to $170 million FY2026 revenue range, with execution against that trajectory serving as the primary near-term catalyst.
Learn more about Red Cat Holdings Inc.
Nova Minerals Ltd. (NASDAQ: NVA)
Source: Nova Minerals Ltd.
Nova Minerals Ltd. (NASDAQ: NVA) controls the Estelle Gold Project in Alaska and is separately advancing an antimony refinery at Port MacKenzie targeting military-specification production in 2026 and 2027, per company disclosures. One analyst tracked by TipRanks carries an average price target of $10.00, implying approximately 72% upside from the current price. Permitting and financing progress at Estelle, alongside the antimony production timeline, represent the near-term catalysts.
Learn more about Nova Mineral Ltd.
NioCorp Developments Ltd. (NASDAQ: NB)
Source: NioCorp Developments Ltd.
NioCorp Developments Ltd. (NASDAQ: NB) is developing the Elk Creek Critical Minerals Project in Nebraska, targeting niobium, scandium, and titanium. The company began mine portal excavation on March 4, 2026, with Congressman Adrian Smith participating. NioCorp raised approximately $100 million in a February 2026 public offering at $5.00 per share. Three analysts on TipRanks carry a Strong Buy consensus with an average price target of $12.25, ranging from a low of $9.50 to a high of $15.00, implying approximately 167% upside at the average. A final investment decision, contingent on full project financing, remains the primary longer-term catalyst.
Learn more about NioCorp Developments Ltd.
Biomea Fusion, Inc. (NASDAQ: BMEA)
Source: Biomea Fusion Inc.
Biomea Fusion, Inc. (NASDAQ: BMEA) is developing covalent small molecule therapies for metabolic disease and cancer, with lead asset icovamenib targeting insulin secretion and beta cell function in Type 1 and Type 2 diabetes. The company presented long-term follow-up data for icovamenib at a major endocrinology conference in early 2026. Six analysts on TipRanks carry a Moderate Buy consensus with an average price target of $7.80, ranging from a low of $4.00 to a high of $12.00, implying approximately 491% upside at the average. The company reports next earnings on May 6, 2026, with clinical data milestones for icovamenib serving as the primary longer-term catalyst.
Learn more about Biomea Fusion Inc.
Market Perspective
Analyst price targets for small-cap companies reflect wide dispersion by nature and should be interpreted as directional research estimates rather than precision forecasts. Several names in this list carry single-analyst coverage, which warrants particular caution. Each company above has a defined near-term catalyst. Execution risk, financing risk, and market risk remain material considerations across all eight. This article is for informational purposes only and does not constitute investment advice.